We are international

IMF Research Grant Summary (1995-2004)
IMF Research Grant Summary (1995-2004)
2004 Dr. Manuel Penichet, M.D., Ph.D,
Associate Researcher University of California, Los Angeles
Brian D. Novis Senior Grant $80,000 Antibody-avidin Fusion Proteins Targeting the Transferrin Receptor: Potential Therapeutics for the Treatment of MM A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL
Biomol Eng. 2005 Feb;21(6):145-55. Epub 2004 Dec 9

Antibody-cytokine fusion proteins: innovative weapons in the war against cancer.
Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Clin Exp Med. 2004 Oct;4(2):57-64.

Dr. Marco Ladetto, Ass't Professor in Hematology, The University of Torino Brian D. Novis $40,000 The role of cyclooxygenase-2 (COX2) in Multiple Myeloma Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
Ladetto M, Vallet S, Trojan A, Dell'aquila M, Monitillo L, Rosato R Blood. 2005 Feb 24; [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15731178
Dr. Chao-Lan Yu, Assistant Professor , Vanderbilt University School of Medicine Brian D. Novis (second year renewal) $40,000 Suppressor of Cytokine Signaling (SOCS): Its Regulation & Potential Implication as a Therapeutic Agent in Multiple Myeloma Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing.
Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ Eur J Immunol. 2004 Sep;34(9):2459-70
Dr. Mathias Oelke, Research Associate, Johns Hopkins University Medical School Brian D. Novis $40,000 Development of artificial antigen presenting cells for adoptive immunotherapy of multiple myeloma Technological advances in adoptive immunotherapy.
Oelke M, Krueger C, Schneck JP.
Drugs Today (Barc). 2005 Jan;41(1):13-21

Quality and quantity: new strategies to improve immunotherapy of cancer.
Krueger C, Schneck JP, Oelke M. Trends Mol Med. 2004 May;10(5):205-8.

LA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.
Oelke M, Schneck JP Clin Immunol. 2004 Mar;110(3):243-51.

Dr. Francesco Piazza, Research Assistant, Venetian Institute of Molecular Medicine, University of Padova Brian D. Novis $40,000 Roles of CK2 and GSK3 serine-threonine kinases in the regulation of proliferative and survival pathways in MM Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Piazza F, Semenzato G Expert Rev Anticancer Ther. 2004 Jun;4(3):387-400.
Dr. Hideaki Ishikawa Yamaguchi University  Aki Horinouchi IMF Japan Investigation of the molecules controlling myeloma cell growth and application for therapy Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S, Ishikawa H, Li FJ, Ma Z, Otsuyama K, Asaoku H, Abroun S, Zheng X Cancer Res. 2005 Mar 15;65(6):2269-76.

Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells.
Ma Z, Otsuyama K, Liu S, Abroun S, Ishikawa H, Tsuyama N Blood. 2005 Apr 15;105(8):3312-8. Epub 2004 Dec 30.

A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma.
Li FJ, Tsuyama N, Ishikawa H, Obata M, Abroun S, Liu S, Otsuyama K, Blood. 2005 Apr 15;105(8):3295-302. Epub 2004 Dec 30.

Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.
Ishikawa H, Tsuyama N, Kawano MM. Int J Hematol. 2003 Aug;78(2):95-105

Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6.
Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O, Kawano MM Blood. 2002 Mar 15;99(6):2172-8
2003 Dr. Chao-Lan Yu
Vanderbilt University
Brian D. Novis $40,000 Suppressor of Cytokine Signaling (SOCS): Its Regulation and Potential Implication as a Therapeutic Agent in Multiple Myeloma Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ, McKay DB.
Am J Transplant. 2002 Jan;2(1):31-40.
Kewal Asosingh Brussels Free University Brian D. Novis $40,000 Tumor-host interactions during multiple myeloma disease progression; functional roles of CD45 subsets Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
Asosingh K, De Raeve H et al.
26 Blood, 15 April 2004, Vol. 103, No. 8, pp. 3131-3137.

Multiple myeloma biology: lessons from the 5TMM models.
Vanderkerken K, Asosingh K, Croucher P, Van Camp B Immunol Rev. 2003 Aug;194:196-206.

Lee-ann Garrett-Sinha State University New York Buffalo Brian D. Novis $40,000 Identification of the Role of Ets-1 in Regulating Plasma Cell Numbers The Ets factors PU.1 and Spi-B regulate the transcription in vivo of P2Y10, a lymphoid restricted heptahelical receptor.
Rao S, Garrett-Sinha LA, Yoon J, Simon MC J Biol Chem. 1999 Nov 26;274(48):34245-52.

PU.1 exhibits partial functional redundancy with Spi-B, but not with Ets-1 or Elf-1.
Garrett-Sinha LA, Dahl R, Rao S, Barton KP, Simon MC. Blood. 2001 May 1;97(9):2908-12.

Sun J. Choi University of Pittsburgh Brian D. Novis $40,000 Effects of Abnormal Expression of AML-1 Transcription Factors on Myeloma Bone Disease IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. Blood. 2004 Mar 15;103(6):2308-15. Epub 2003 Nov 13.

Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ.
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Choi SJ, Roodman GD. Exp Hematol. 2005 Mar;33(3):272-8.

MIP-1 alpha and myeloma bone disease.
Roodman GD, Choi SJ. Cancer Treat Res. 2004;118:83-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=DisplayFiltered&DB=pubmed
AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.
Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD Blood. 2003 May 15;101(10):3778-83. Epub 2003 Jan 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12560229&itool=iconfft

2002 Herve Avet-Loiseau  Institute de Biologie, France Senior Grant (Continuing Support) $80,000
Elliot Epner University of Arizona, University of Oregon Senior Grant (Continuing Support) $80,000 Targeted deletion of the chicken beta -globin regulatory elements reveals a cooperative gene silencing activity.
Wang J, Liu H, Lin CM, Aladjem MI, Epner EM. J Biol Chem. 2005 Apr 11; [Epub ahead of print]

Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences.
Liu H, Wang J, Epner EM. Blood. 2004 Oct 15;104(8):2505-13. Epub 2004 Jun 29.

Replication initiation patterns in the beta-globin loci of totipotent and differentiated murine cells: evidence for multiple initiation regions.
Aladjem MI, Rodewald LW, Lin CM, Bowman S, Cimbora DM, Brody LL, Epner EM, Mol Cell Biol. 2002 Jan;22(2):442-52.

Long-distance control of origin choice and replication timing in the human beta-globin locus are independent of the locus control region.
Cimbora DM, Schubeler D, Reik A, Hamilton J, Francastel C, Epner EM Mol Cell Biol. 2000 Aug;20(15):5581-91.

Masahiro Abe, Department of Medicine, University of Tokushima Graduate School of Medicine, Japan IMF Japan $25,000 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.
Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K Blood. 2004 Oct 15;104(8):2484-91. Epub 2004 Jun 8

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
Hashimoto T, Abe M, Oshima T, Shibata H Br J Haematol. 2004 Apr;125(1):38-41.

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe M, Hiura K, Wilde J, Moriyama K Blood. 2002 Sep 15;100(6):2195-202.

Michael A. Morgan  Hannover Medical School, Hannover, Germany Brian D. Novis $40,000 Gene silencing mediated by small interfering RNAs in mammalian cells.
Scherr M, Morgan MA, Eder M. Curr Med Chem. 2003 Feb;10(3):245-56 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12570711

Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Morgan MA, Dolp O, Reuter CW. Blood. 2001 Mar 15;97(6):1823-34.

Jamie Claudio  Ontario Cancer Institute - Canada Brian D. Novis $40,000 The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades.
Zhu YX, Benn S, Li ZH, Wei E, Masih-Khan E, Trieu Y, Bali M, McGlade CJ, Claudio JO J Exp Med. 2004 Sep 20;200(6):737-47.

Insights from the gene expression profiling of multiple myeloma.
Claudio JO, Masih-Khan E, Stewart AK.? Curr Hematol Rep. 2004 Jan;3(1):67-73 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14695854&itool=iconabstr

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J Blood. 2003 Jul 15;102(2):772-3.

Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
Claudio JO, Stewart AK. Am J Pharmacogenomics. 2005;5(1):35-43

Amit Nathwani  University College London Medical School - England Brian D. Novis $40,000 Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability.
Davidoff AM, Ng CY, Zhang Y, Streck CJ, Mabry SJ, Barton SH, Baudino T, Zhou J, Kerbel RS, Vanin EF, Nathwani AC. Mol Ther. 2005 Feb;11(2):300-10.

A review of gene therapy for haematological disorders.
Nathwani AC, Davidoff AM, Linch DC. Br J Haematol. 2005 Jan;128(1):3-17.

Current status and prospects for gene therapy.
Nathwani AC, Benjamin R, Nienhuis AW, Davidoff AM. Vox Sang. 2004 Aug;87(2):73-81.

Antiangiogenic gene therapy for cancer treatment.
Davidoff AM, Nathwani AC. Curr Hematol Rep. 2004 Jul;3(4):267-73

Atanasio Pandiella Centro de Investigacion del Cancer, Spain Brian D. Novis $40,000 N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.
Juanes PP, Ferreira L, Montero JC, Arribas J, Pandiella A. Biochem J. 2005 Mar 18; [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15777285&itool=iconabstr

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.
Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, San Miguel JF. Br J Haematol. 2003 Dec;123(5):858-68.

Multifunctional role of Erk5 in multiple myeloma.
Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, Mateo G, Gutierrez N, Parmo-Cabanas M, Teixido J, San Miguel JF, Pandiella A. Blood. 2005 Feb 3; [Epub ahead of print]

Klaus Podar  Dana-Farber Cancer Institute Brian D. Novis (Continuing Support) $40,000 The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
Podar K, Anderson KC. Blood. 2005 Feb 15;105(4):1383-95. Epub 2004 Oct 7.

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T Cancer Res. 2002 Sep 1;62(17):5019-26.

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P Blood. 2004 May 1;103(9):3474-9. Epub 2003 Nov 26

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.
Tai YT, Podar K, Gupta D, Lin B, Young G Blood. 2002 Feb 15;99(4):1419-27.

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
Podar K, Tai YT, Lin BK, Narsimhan RP J Biol Chem. 2002 Mar 8;277(10):7875-81. Epub 2001 Dec 20.

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T Blood. 2001 Jul 15;98(2):428-35.

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Gupta D, Treon SP, Shima Y, Hideshima T, Podar K Leukemia. 2001 Dec;15(12):1950-61.

Ivan Van Riet Free University Brussels, Belgium Brian D. Novis (Continuing Support) $40,000
2001 Herve Avet-Loiseau, Institut de Biologie, Nantes, France Senior Grant $80,000 Microarray analysis of primary multiple myeloma specimens
Robert G. Fenton, University of Maryland, U.S Senior Grant $80,000 A high-throughput assay for inhibitors of STAT 3 signaling
Amir Toor, University of Arkansas, U.S Brian D. Novis $40,000 DNA double strand break repair by non-homologous end joining in multiple myeloma Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92.

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.
Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A Blood. 2004 Dec 1;104(12):3697-704. Epub 2004 Aug 3.

Daniel Sze, Royal Prince Alfred Hospital, Sydney, Australia  Brian D. Novis $40,000 Identification of the specificity of potential myeloma-specific clonal CD8 T cells using TCR transfectants Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.
Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, Baxter AG, Fazekas de St Groth B, Basten A, Joshua DE. Blood. 2001 Nov 1;98(9):2817-27.

Experimental models linking dendritic cell lineage, phenotype and function.
Fazekas De St Groth B, L Smith A, Bosco J, Sze DM, Power CA, Austen FI. Immunol Cell Biol. 2002 Oct;80(5):469-76.

Clonal cytotoxic T cells in myeloma.
Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, Basten A, Joshua DE, Leuk Lymphoma. 2003 Oct;44(10):1667-74

B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation.
Brown R, Murray A, Pope B, Sze D, Gibson J, Ho PJ, Joshua D. Leuk Lymphoma. 2004 Feb;45(2):363-71.

Klaus Podar, Dana Farber Cancer Institute, U.S.  Brian D. Novis $40,000 The pathophysiological relevance of VEGF in multiple myeloma See Podar 2002
Rudi Hrncic, University of Tennessee, U.S. Brian D. Novis $40,000 Immunotherapy & molecular diagnosis of Al Amyloidosis (third year funding recipient) Calcifying epithelial odontogenic (Pindborg) tumor-associated amyloid consists of a novel human protein.
Solomon A, Murphy CL, Weaver K, Weiss DT, Hrncic R, Eulitz M, Donnell RL, Sletten K, Westermark G, Westermark P. J Lab Clin Med. 2003 Nov;142(5):348-55
Elliot Epner, University of Arizona, U.S. Brian D. Novis $40,000 Cyclin DI deregulation in multiple myeloma See Epner 2003
Nancy Borson, Mayo Clinic, U.S. Brian D. Novis $40,000 In-vivo analysis of isoforms of B-cell Specific Activating Protein (BSAP) in malignant and normal bone marrows Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma.
Borson ND, Lacy MQ, Wettstein PJ. Blood. 2002 Dec 15;100(13):4629-39.
2000 Dr. Elliot Epner - The University of Arizona $40,000 Genetic Analysis of Gene Detegulation by Immunoglobulin Regulatory Sequences in Multiple Myeloma See Epner 2003.
Roger N. Pearse, M.D., Ph.D.,
Rockefeller University 
Second year renewal $40,000 The Role of the Osteoclast Differentiation Factor TRANCE in Myeloma Associated - Associated Bone Destruction
Dr. Scott Schuetze- Sarcoma Clinic, University of Michigan Klein Grant $40,000 Cloning and Characterization of Myeloma Idiotype Specific T Cell none related
Dr. Hon Jin Mark Ma - Brentwood Basic Research Institute L.A. Support Group $40,000 Human Serum Antibodies to a Major Defined Epitope of Myeloma Specific Human Herpesvirus 8 Small Viral Capsid Antigen Human herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma.
Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M Clin Cancer Res. 2000 Nov;6(11):4226-33

Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution.
Pold M, Pold A, Ma HJ, Sjak-Shieb NN, Vescio RA, Berensonb JR. Dev Comp Immunol. 2000 Dec;24(8):719-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10906385

Dr. Rudi Hrncic - University of Tennessee  Brian D. Novis

 related articles